JPMorgan raised the firm’s price target on Alnylam (ALNY) to $475 from $348 and keeps an Overweight rating on the shares. The company reported an “exceptionally strong Q2 and guidance increase, the analyst tells investors in a research note. The firm continues to see a “healthy launch” ahead for Amvuttra.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Coinbase downgraded, Spotify upgraded: Wall Street’s top analyst calls
- Alnylam upgraded to Peer Perform from Underperform at Wolfe Research
- Oppenheimer upgrades Alnylam to Outperform on Amvuttra launch
- Alnylam upgraded to Outperform from Perform at Oppenheimer
- Alnylam Pharma: Hold Rating Amid Strong Sales and Elevated Costs